Ticker Details
Karyopharm Therapeutics Inc. Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.
IPO Date:	November 6, 2013
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$231.16M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.41 | 3.81%
Avg Daily Range (30 D):	$0.35 | 3.76%
Avg Daily Range (90 D):	$0.34 | 4.08%

Institutional Daily Volume
Avg Daily Volume:	.2M
Avg Daily Volume (30 D):	.35M
Avg Daily Volume (90 D):	.72M

Trade Size
Avg Trade Size (Sh.):	29
Avg Trade Size (Sh.) (30 D):	71
Avg Trade Size (Sh.) (90 D):	106

Institutional Trades
Total Institutional Trades:	2,386
Avg Institutional Trade:	$1.65M
Avg Institutional Trade (30 D):	$2.24M
Avg Institutional Trade (90 D):	$1.93M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.88M
Avg Closing Trade (30 D):	$2.83M
Avg Closing Trade (90 D):	$2.31M
Avg Closing Volume:	18.81K

News

Jun 14, 2026 @ 10:30 AM Menarini Group Reports Data from the Phase 3 SENTR... Source: Na

Mar 1, 2025 @ 1:45 PM International Myeloma Foundation (IMF) Celebrates ... Source: International Myeloma Foundation

Nov 25, 2024 @ 4:00 PM Glioblastoma Multiforme Treatment Market Size to R... Source: Precedence Research

Sep 5, 2024 @ 6:16 PM Down -12.14% in 4 Weeks, Here's Why Karyopharm The... Source: Zacks

Jul 8, 2024 @ 5:02 PM Advanced Melanoma Clinical Trial Pipeline Analysis... Source: Delveinsight

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-16.16	$-1.02	$-7
Diluted EPS	$-16.38	$-1.24	$-7
Revenue	$151.12M	$35.07M	$34.08M
Gross Profit
Net Income / Loss	$-194.97M	$-22.39M	$-102.2M
Operating Income / Loss	$-84.21M	$-26.76M	$-17.84M
Cost of Revenue
Net Cash Flow	$28.36M	$30.28M	$22.87M
PE Ratio

Splits
Feb 26, 2025	1:15